These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 30969381)

  • 1. Successful resection of intrahepatic cholangiocarcinoma with idiopathic thrombocytopenic purpura using thrombopoietin receptor agonist: a case report.
    Hoshino K; Harimoto N; Muranushi R; Araki K; Yamanaka T; Hagiwara K; Ishii N; Tsukagoshi M; Igarashi T; Tanaka H; Watanabe A; Kubo N; Yokobori T; Shirabe K
    Surg Case Rep; 2019 Apr; 5(1):56. PubMed ID: 30969381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations.
    Aoki T; Harada Y; Matsubara E; Suzuki T; Oyama T; Kasai M; Uchida T; Ogura M
    J Clin Pharm Ther; 2012 Dec; 37(6):729-32. PubMed ID: 22583038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thrombopoietin receptor agonist (TPO-RA) treatment raises platelet counts and reduces anti-platelet antibody levels in mice with immune thrombocytopenia (ITP).
    Kapur R; Aslam R; Speck ER; Rebetz JM; Semple JW
    Platelets; 2020; 31(3):399-402. PubMed ID: 31146647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of Eltrombopag for the First Trimester Pregnancy Complicated with Refractory Idiopathic Thrombocytopenic Purpura: A Case Report and Literature Review.
    Shibata S; Misugi T; Nakane T; Hino M; Tachibana D
    Cureus; 2022 Feb; 14(2):e22505. PubMed ID: 35371812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Successful switching from eltrombopag to romiplostim in a pediatric patient with refractory chronic ITP].
    Mori M; Kato M; Koh K; Hanada R
    Rinsho Ketsueki; 2015 May; 56(5):511-3. PubMed ID: 26062675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Platelet Kinetics in Idiopathic Thrombocytopenic Purpura Patients Treated with Thrombopoietin Receptor Agonists.
    Meyer O; Herzig E; Salama A
    Transfus Med Hemother; 2012 Feb; 39(1):5-8. PubMed ID: 22896760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TPO receptor agonist for chronic idiopathic thrombocytopenic purpura.
    Zeng Y; Duan X; Xu J; Ni X
    Cochrane Database Syst Rev; 2011 Jul; 2011(7):CD008235. PubMed ID: 21735426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased microvesicle-associated thrombin generation in patients with immune thrombocytopenia after initiation of thrombopoietin receptor agonists.
    Garabet L; Ghanima W; Hellum M; Sandset PM; Bussel JB; Tran H; Henriksson CE
    Platelets; 2020; 31(3):322-328. PubMed ID: 31280643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Thrombopoietin receptor agonists administration for acute exacerbation of chronic idiopathic thrombocytopenic purpura and subsequent anticoagulant therapy for accompanying deep venous thrombosis of the lower limbs].
    Kawano H; Suzuki T; Ishii S; Wakahashi K; Kawano Y; Sada A; Minagawa K; Takaya T; Yamashita T; Hirata K; Koriyama K; Nagamatsu Y; Matsui T; Katayama Y
    Rinsho Ketsueki; 2014 Jun; 55(6):697-702. PubMed ID: 24975340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: results of a retrospective, observational GIMEMA study.
    Zaja F; Barcellini W; Cantoni S; Carpenedo M; Caparrotti G; Carrai V; Di Renzo N; Santoro C; Di Nicola M; Veneri D; Simonetti F; Liberati AM; Ferla V; Paoloni F; Crea E; Volpetti S; Tuniz E; Fanin R
    Am J Hematol; 2016 May; 91(5):E293-5. PubMed ID: 26910388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained remission of chronic immune thrombocytopenia after discontinuation of treatment with thrombopoietin-receptor agonists in adults.
    Červinek L; Mayer J; Doubek M
    Int J Hematol; 2015 Jul; 102(1):7-11. PubMed ID: 25833724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thrombopoietin Receptor Agonist Use in Children: Data From the Pediatric ITP Consortium of North America ICON2 Study.
    Neunert C; Despotovic J; Haley K; Lambert MP; Nottage K; Shimano K; Bennett C; Klaassen R; Stine K; Thompson A; Pastore Y; Brown T; Forbes PW; Grace RF;
    Pediatr Blood Cancer; 2016 Aug; 63(8):1407-13. PubMed ID: 27135461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Romiplostim in chronic immune thrombocytopenic purpura.
    Cersosimo RJ
    Clin Ther; 2009 Sep; 31(9):1887-907. PubMed ID: 19843480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of thrombopoietin receptor agonists in children with chronic immune thrombocytopenic purpura: meta-analysis.
    Tumaini Massaro J; Chen Y; Ke Z
    Platelets; 2019; 30(7):828-835. PubMed ID: 30810479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment patterns and clinical outcomes in patients with chronic immune thrombocytopenia (ITP) switched to eltrombopag or romiplostim.
    Kuter DJ; Macahilig C; Grotzinger KM; Poston SA; Wang PF; Dawson KL; Ward M
    Int J Hematol; 2015 Mar; 101(3):255-63. PubMed ID: 25586660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of thrombopoietin receptor agonists on leukocyte and haematopoietic stem and progenitor cells in the peripheral blood of patients with immune thrombocytopenic purpura.
    Bal G; Fabian D; Maia D; Ringel F; Salama A
    Ann Hematol; 2017 Dec; 96(12):2045-2056. PubMed ID: 28965224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thrombopoietin level predicts response to treatment with eltrombopag and romiplostim in immune thrombocytopenia.
    Al-Samkari H; Kuter DJ
    Am J Hematol; 2018 Dec; 93(12):1501-1508. PubMed ID: 30187942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Severe romiplostim-induced rebound thrombocytopenia after splenectomy for refractory ITP.
    Choe MJ; Packer CD
    Ann Pharmacother; 2015 Jan; 49(1):140-4. PubMed ID: 25325908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Thrombosis during thrombopoietin receptor agonist treatment for immune thrombocytopenia. A French multicentric observational study].
    Weber E; Moulis G; Mahévas M; Guy C; Lioger B; Durieu I; Hunault M; Ramanantsoa M; Royer B; Default A; Pérault-Pochat MC; Moachon L; Bernard N; Bardy G; Jonville-Bera AP; Geniaux H; Godeau B; Cathébras P
    Rev Med Interne; 2017 Mar; 38(3):167-175. PubMed ID: 27793553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of adding rituximab to splenectomy and romiplostim for treating steroid-resistant idiopathic thrombocytopenic purpura in adults.
    Kikuchi K; Miyakawa Y; Ikeda S; Sato Y; Takebayashi T
    BMC Health Serv Res; 2015 Jan; 15():2. PubMed ID: 25609557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.